HRP20090618T1 - Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka - Google Patents
Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka Download PDFInfo
- Publication number
- HRP20090618T1 HRP20090618T1 HR20090618T HRP20090618T HRP20090618T1 HR P20090618 T1 HRP20090618 T1 HR P20090618T1 HR 20090618 T HR20090618 T HR 20090618T HR P20090618 T HRP20090618 T HR P20090618T HR P20090618 T1 HRP20090618 T1 HR P20090618T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- sub
- moiety
- shock
- treatment
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 11
- 230000035939 shock Effects 0.000 title claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 102000009123 Fibrin Human genes 0.000 claims abstract 4
- 108010073385 Fibrin Proteins 0.000 claims abstract 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims abstract 4
- 229950003499 fibrin Drugs 0.000 claims abstract 4
- 102000008790 VE-cadherin Human genes 0.000 claims abstract 3
- 230000004071 biological effect Effects 0.000 claims abstract 3
- 108010018828 cadherin 5 Proteins 0.000 claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims abstract 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 2
- 210000000056 organ Anatomy 0.000 claims 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000712892 Arenaviridae Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 206010022657 Intestinal infarction Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 208000006193 Pulmonary infarction Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 206010019680 hepatic infarction Diseases 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000007970 necrotizing fasciitis Diseases 0.000 claims 1
- 230000007575 pulmonary infarction Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0108704A AT414097B (de) | 2004-06-25 | 2004-06-25 | Pharmazeutische zubereitung zur behandlung von schock |
| AT0004005A AT501263B1 (de) | 2005-01-13 | 2005-01-13 | Pharmazeutische zubereitung zur behandlung von schock |
| PCT/AT2005/000228 WO2006000007A1 (de) | 2004-06-25 | 2005-06-24 | Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090618T1 true HRP20090618T1 (hr) | 2010-01-31 |
Family
ID=35058593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090618T HRP20090618T1 (hr) | 2004-06-25 | 2009-11-18 | Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080249006A1 (es) |
| EP (1) | EP1691827B1 (es) |
| JP (1) | JP2008503503A (es) |
| AT (1) | ATE439856T1 (es) |
| AU (1) | AU2005256121B2 (es) |
| BR (1) | BRPI0506148A (es) |
| CA (1) | CA2544676A1 (es) |
| CY (1) | CY1109631T1 (es) |
| DE (1) | DE502005007926D1 (es) |
| DK (1) | DK1691827T3 (es) |
| EA (1) | EA008799B1 (es) |
| ES (1) | ES2331958T3 (es) |
| HK (1) | HK1093308A1 (es) |
| HR (1) | HRP20090618T1 (es) |
| IL (1) | IL173969A (es) |
| NZ (1) | NZ545634A (es) |
| PL (1) | PL1691827T3 (es) |
| PT (1) | PT1691827E (es) |
| SI (1) | SI1691827T1 (es) |
| WO (1) | WO2006000007A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT502987A1 (de) * | 2005-12-23 | 2007-07-15 | Fibrex Medical Res & Dev Gmbh | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| WO2007095660A1 (en) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| ES2333374T3 (es) | 2006-02-23 | 2010-02-19 | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH | Peptidos y derivados de peptidos, la produccion de los mismos asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa. |
| WO2007095659A1 (de) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels |
| EP2193370A2 (en) * | 2007-09-24 | 2010-06-09 | Fibrex Medical Research & Development GmbH | Methods of screening for compounds having anti-inflammatory activity |
| WO2009096502A1 (ja) * | 2008-01-31 | 2009-08-06 | Japan As Represented By President Of National Center Of Neurology And Psychiatry | うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断 |
| US7884074B2 (en) | 2008-05-15 | 2011-02-08 | Ikaria Development Subsidiary Two, LLC | Compounds and methods for prevention and/or treatment of inflammation using the same |
| US8088890B2 (en) * | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| WO2010043444A2 (en) * | 2008-10-15 | 2010-04-22 | Fibrex Medical Research & Development Gmbh | Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965107A (en) * | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| DE19729591A1 (de) * | 1997-07-10 | 1999-02-11 | Therasorb Medizinische Systeme | Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen |
| ATE425184T1 (de) * | 2000-12-12 | 2009-03-15 | Fibrex Medical Res & Dev Gmbh | Peptide und/oder proteine sowie ihre verwendung zur herstellung eines therapeutischen und/oder präventiven arzneimittels |
| WO2002069960A2 (en) * | 2001-03-06 | 2002-09-12 | Axxima Pharmaceuticals Ag | Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| WO2007095660A1 (en) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
-
2005
- 2005-06-24 AU AU2005256121A patent/AU2005256121B2/en not_active Ceased
- 2005-06-24 BR BRPI0506148-2A patent/BRPI0506148A/pt not_active IP Right Cessation
- 2005-06-24 CA CA002544676A patent/CA2544676A1/en not_active Abandoned
- 2005-06-24 DK DK05752350T patent/DK1691827T3/da active
- 2005-06-24 AT AT05752350T patent/ATE439856T1/de active
- 2005-06-24 SI SI200530842T patent/SI1691827T1/sl unknown
- 2005-06-24 WO PCT/AT2005/000228 patent/WO2006000007A1/de not_active Application Discontinuation
- 2005-06-24 EA EA200600561A patent/EA008799B1/ru not_active IP Right Cessation
- 2005-06-24 US US10/596,103 patent/US20080249006A1/en not_active Abandoned
- 2005-06-24 NZ NZ545634A patent/NZ545634A/en not_active IP Right Cessation
- 2005-06-24 PT PT05752350T patent/PT1691827E/pt unknown
- 2005-06-24 DE DE502005007926T patent/DE502005007926D1/de active Active
- 2005-06-24 ES ES05752350T patent/ES2331958T3/es active Active
- 2005-06-24 JP JP2007516870A patent/JP2008503503A/ja active Pending
- 2005-06-24 EP EP05752350A patent/EP1691827B1/de active Active
- 2005-06-24 PL PL05752350T patent/PL1691827T3/pl unknown
-
2006
- 2006-02-27 IL IL173969A patent/IL173969A/en not_active IP Right Cessation
- 2006-12-27 HK HK06114161.8A patent/HK1093308A1/xx not_active IP Right Cessation
-
2009
- 2009-11-13 CY CY20091101198T patent/CY1109631T1/el unknown
- 2009-11-18 HR HR20090618T patent/HRP20090618T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1691827B1 (de) | 2009-08-19 |
| NZ545634A (en) | 2009-09-25 |
| JP2008503503A (ja) | 2008-02-07 |
| CA2544676A1 (en) | 2006-01-05 |
| EP1691827A1 (de) | 2006-08-23 |
| ATE439856T1 (de) | 2009-09-15 |
| PL1691827T3 (pl) | 2010-01-29 |
| DK1691827T3 (da) | 2009-12-14 |
| WO2006000007A1 (de) | 2006-01-05 |
| AU2005256121B2 (en) | 2011-03-03 |
| DE502005007926D1 (de) | 2009-10-01 |
| US20080249006A1 (en) | 2008-10-09 |
| CY1109631T1 (el) | 2014-08-13 |
| SI1691827T1 (sl) | 2010-01-29 |
| EA008799B1 (ru) | 2007-08-31 |
| ES2331958T3 (es) | 2010-01-21 |
| AU2005256121A1 (en) | 2006-04-27 |
| EA200600561A1 (ru) | 2006-08-25 |
| BRPI0506148A (pt) | 2006-10-24 |
| IL173969A (en) | 2011-06-30 |
| IL173969A0 (en) | 2006-07-05 |
| HK1093308A1 (en) | 2007-03-02 |
| PT1691827E (pt) | 2009-11-23 |
| AU2005256121A8 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090618T1 (hr) | Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka | |
| AU2007283150B2 (en) | Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer | |
| HRP20161416T1 (hr) | Novi transportni konstrukti i transportne nosive konjugirane molekule | |
| JP2018171063A5 (es) | ||
| JP4423542B2 (ja) | 抗菌性ポリペプチド及びその利用 | |
| RU2011135755A (ru) | Антибиотические пептиды | |
| AR036196A1 (es) | Agentes de contraste multimericos dirigidos a base de peptidos | |
| JP6553706B2 (ja) | 抗微生物ペプチドデンドリマー | |
| JP2001512739A (ja) | 抗生作用ペプチドから誘導される線状ペプチド、製法および活性物質を仲介する用途 | |
| JP2015534972A5 (es) | ||
| Jakubke et al. | Peptides from A to Z: a concise encyclopedia | |
| Tsugita et al. | Comparative study of the primary structures of cytochrome b 5 from four species | |
| JPH02500517A (ja) | ペプチド化合物 | |
| JP4338516B2 (ja) | 血管新生剤 | |
| MX2022003057A (es) | Nuevos peptidos. | |
| UA91497C2 (ru) | ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА | |
| CA2196053A1 (en) | Two non-contiguous regions contribute to nidogen binding to a single egf-like motif of the laminin .gamma.1 chain | |
| TW209171B (es) | ||
| JP2002534996A5 (es) | ||
| JP7475051B2 (ja) | 新規化合物及びそれを含む血管新生剤 | |
| Henriques et al. | Discovery of peptide drugs from natural sources | |
| JP5673596B2 (ja) | 細胞膜透過性を有する製剤及び細胞膜透過性組成物 | |
| DE202015006574U1 (de) | Peptid zur Beschichtung von Oberflächen | |
| Wahyudi et al. | Targeting Disease-Related Proteins via Secondary Protein Structure Formation | |
| JPWO2020066343A1 (ja) | 細胞膜透過性ペプチド |